Bio-Techne Past Earnings Performance
Past criteria checks 1/6
Bio-Techne has been growing earnings at an average annual rate of 12.9%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 11.8% per year. Bio-Techne's return on equity is 10.1%, and it has net margins of 17.6%.
Key information
12.9%
Earnings growth rate
12.0%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 11.8% |
Return on equity | 10.1% |
Net Margin | 17.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
May 26Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
May 13Revenue & Expenses BreakdownBeta
How Bio-Techne makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1,154 | 203 | 438 | 96 |
31 Dec 23 | 1,145 | 224 | 420 | 93 |
30 Sep 23 | 1,144 | 247 | 406 | 93 |
30 Jun 23 | 1,137 | 285 | 397 | 92 |
31 Mar 23 | 1,124 | 271 | 401 | 92 |
31 Dec 22 | 1,120 | 262 | 392 | 91 |
30 Sep 22 | 1,118 | 292 | 400 | 89 |
30 Jun 22 | 1,106 | 272 | 392 | 87 |
31 Mar 22 | 1,076 | 225 | 361 | 85 |
31 Dec 21 | 1,030 | 210 | 350 | 80 |
30 Sep 21 | 985 | 177 | 334 | 76 |
30 Jun 21 | 931 | 140 | 312 | 71 |
31 Mar 21 | 848 | 184 | 296 | 67 |
31 Dec 20 | 799 | 175 | 282 | 66 |
30 Sep 20 | 760 | 248 | 271 | 65 |
30 Jun 20 | 739 | 229 | 267 | 65 |
31 Mar 20 | 755 | 187 | 273 | 65 |
31 Dec 19 | 745 | 195 | 271 | 64 |
30 Sep 19 | 734 | 93 | 266 | 64 |
30 Jun 19 | 714 | 96 | 262 | 62 |
31 Mar 19 | 703 | 121 | 257 | 60 |
31 Dec 18 | 682 | 96 | 244 | 58 |
30 Sep 18 | 661 | 128 | 232 | 57 |
30 Jun 18 | 643 | 126 | 216 | 55 |
31 Mar 18 | 619 | 112 | 194 | 55 |
31 Dec 17 | 599 | 114 | 187 | 55 |
30 Sep 17 | 577 | 73 | 183 | 54 |
30 Jun 17 | 563 | 76 | 175 | 54 |
31 Mar 17 | 541 | 74 | 170 | 51 |
31 Dec 16 | 528 | 82 | 158 | 49 |
30 Sep 16 | 517 | 101 | 145 | 47 |
30 Jun 16 | 499 | 104 | 138 | 45 |
31 Mar 16 | 482 | 105 | 130 | 44 |
31 Dec 15 | 465 | 99 | 125 | 44 |
30 Sep 15 | 456 | 107 | 121 | 43 |
30 Jun 15 | 452 | 108 | 115 | 41 |
31 Mar 15 | 427 | 108 | 101 | 38 |
31 Dec 14 | 408 | 116 | 86 | 34 |
30 Sep 14 | 380 | 107 | 71 | 32 |
30 Jun 14 | 358 | 111 | 60 | 31 |
31 Mar 14 | 345 | 113 | 54 | 30 |
31 Dec 13 | 330 | 114 | 50 | 30 |
30 Sep 13 | 321 | 114 | 46 | 30 |
30 Jun 13 | 311 | 113 | 43 | 29 |
Quality Earnings: TECH has a large one-off gain of $66.4M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: TECH's current net profit margins (17.6%) are lower than last year (24.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TECH's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: TECH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TECH had negative earnings growth (-25.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.6%).
Return on Equity
High ROE: TECH's Return on Equity (10.1%) is considered low.